1. Home
  2. BSX vs ARGX Comparison

BSX vs ARGX Comparison

Compare BSX & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Scientific Corporation

BSX

Boston Scientific Corporation

N/A

Current Price

$43.68

Market Cap

68.0B

Sector

Health Care

ML Signal

N/A

Logo argenx SE

ARGX

argenx SE

N/A

Current Price

$945.97

Market Cap

55.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BSX
ARGX
Founded
1979
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.0B
55.1B
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
BSX
ARGX
Price
$43.68
$945.97
Analyst Decision
Buy
Buy
Analyst Count
31
25
Target Price
$49.60
★ $1,150.61
AVG Volume (30 Days)
★ 18.1M
377.7K
Earning Date
10-28-2026
10-22-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 55.20
N/A
EPS
★ 1.92
N/A
Revenue
★ $9,076,000,000.00
N/A
Revenue This Year
$4.46
$53.06
Revenue Next Year
N/A
$23.03
P/E Ratio
★ $22.42
$33.69
Revenue Growth
★ 12.49
N/A
52 Week Low
$39.57
$661.85
52 Week High
$101.91
$1,072.75

Technical Indicators

Market Signals
Indicator
BSX
ARGX
Relative Strength Index (RSI) 45.65 55.50
Support Level $42.31 $934.19
Resistance Level $46.31 $1,072.75
Average True Range (ATR) 1.61 26.19
MACD -0.10 4.75
Stochastic Oscillator 25.83 64.22

Price Performance

Historical Comparison
BSX
ARGX

About BSX Boston Scientific Corporation

Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: